IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study to evaluate the safety and tolerability of IBI334 and
determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI334.